Vaccine News and Research

Latest Vaccine News and Research

BIOTECanada congratulates CPHA on 100 years of leadership in public health

As a community partner of the Canadian Public Health Association, BIOTECanada, on behalf of Canada's biotechnology industry, congratulates the CPHA on 100 years of leadership in public health.

11 Jun 2010

FDA grants orphan drug designation for ICT-107

ImmunoCellular Therapeutics announced today that the U.S. Food and Drug Administration has granted orphan drug designation for ICT-107, the company's dendritic cell-based cancer vaccine candidate which targets glioblastoma multiforme. As a result of the orphan drug status, ImmunoCellular will be eligible to receive a number of benefits, including access to grant funding for clinical trials, tax credits, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of up to seven years.

11 Jun 2010

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Amorfix Life Sciences, a company focused on the development of therapeutic monoclonal antibodies and diagnostics for the treatment of fatal neurodegenerative diseases and cancer, today announced its operational and financial results for the year ended March 31, 2010, as well as financial results for the fourth quarter.

11 Jun 2010

Investment report on Novavax

MicroStockProfit.com announces an investment report featuring Novavax Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

11 Jun 2010

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

As a longstanding partner in Canada's public health system, sanofi pasteur congratulates the Canadian Public Health Association (CPHA) for their 100 years of leadership and service to our country's public health.

11 Jun 2010

Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

Innovaro, a comprehensive innovation solutions company, is pleased to announce that it has facilitated the completion of a licensing transaction between Trojan Technologies USA, a company recently formed by Verdant Ventures Advisors II, LLC, and Trojantec Ltd, a London and Cyprus based biopharmaceutical company.

11 Jun 2010

WHO Director-General responds to criticisms over agency's H1N1 response

WHO Director-General Margaret Chan on Tuesday rejected recent criticisms that her decisions to declare H1N1 (swine flu) a pandemic were impacted by her advisers' link to the pharmaceutical industry, the Associated Press reports.

11 Jun 2010

CPL Biologicals completes construction of vaccine facility in Dholka, India

CPL Biologicals (CPLB), a joint venture of Cadila Pharmaceuticals Ltd. and Novavax, Inc., today announced that it has completed construction of its vaccine facility in Dholka, India and will commence equipment and installation validation this month so that the facility conforms to global standards for production of vaccines for human use.

10 Jun 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

2010 International Conference on Emerging Infectious Diseases at Atlanta, Georgia

Journalists are invited to attend and cover the 2010 International Conference on Emerging Infectious Diseases (ICEID), to be held July 11-14, 2010, at the Hyatt Regency, Atlanta, Georgia. The meeting is being organized by the Centers for Disease Control and Prevention (CDC), the American Society for Microbiology, the Council of State and Territorial Epidemiologists, the Association of Public Health Laboratories and the World Health Organization.

10 Jun 2010

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Regeneron Pharmaceuticals, Inc. announced that a Phase 3 study in gout patients initiating allopurinol therapy to lower their uric acid levels showed that ARCALYST (rilonacept), also known as IL-1 Trap, prevented gout attacks, as measured by the primary endpoint of the number of gout flares per patient over the 16 week treatment period.

9 Jun 2010

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.

9 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Northwest Biotherapeutics, Inc., developer of the DCVax personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group.

9 Jun 2010

Experts call on international community to commit attention and resources to cervical cancer prevention

Women's health leaders today called on the international community to commit the resources needed to ensure that women and girls worldwide have equal access to cervical cancer prevention technologies. At the WOMEN DELIVER conference, the Declaration for Universal Access to Cervical Cancer Prevention was issued by leading women's health, cancer and business organizations, including PATH, the International Planned Parenthood Federation and the International Union Against Cancer.

9 Jun 2010

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.

9 Jun 2010

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

The Cancer Research Institute, a nonprofit organization dedicated to the development of immune system-based treatments for cancer, announced today its celebration of a significant new breakthrough in the treatment of melanoma, the deadliest form of skin cancer. The new treatment, a cancer immunotherapy created by Cancer Research Institute Scientific Advisory Council Associate Director James P. Allison, Ph.D., is designed to "take the brakes off the immune system," and is the first treatment ever proven to extend life for patients whose melanomas are unresponsive to existing cancer therapies.

9 Jun 2010

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

An inexpensive system for earlier disease diagnosis could save innumerable lives. It would also have a profound impact on the nation's healthcare industry, currently buckling under the strain of spiraling costs.

9 Jun 2010

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

The Norwegian biopharmaceutical company Lytix Biopharma and Korean company KAEL-GemVax today announced approval by the Norwegian Medicines Agency ('Statens Legemiddelverk') to test a combination of LTX-315 and GV1001 as vaccine therapy in patients with resected tumours. Lytix Biopharma CEO Gunnar Salid states, "We are delighted to announce the approval of our joint study to test a combination of two very interesting experimental drugs.

9 Jun 2010

Gates Foundation announces 5-year, $1.5 billion commitment for maternal, child health

During the Women Deliver conference on Monday Melinda Gates announced that the Bill & Melinda Gates Foundation "will spend $1.5 billion over the next five years on maternal and child health, family planning and nutrition in developing countries, a pledge that signals a new focus for the foundation known for concentrating on vaccines and AIDS," the Wall Street Journal reports (Jordan, 6/7).

9 Jun 2010

Vaccine News and Research

Latest Vaccine News and Research

BIOTECanada congratulates CPHA on 100 years of leadership in public health

FDA grants orphan drug designation for ICT-107

Amorfix Life Sciences reports operational and year-end financial results for fiscal 2010

Investment report on Novavax

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

Innovaro facilitates protein transduction technology licensing between Trojan Technologies, Trojantec

WHO Director-General responds to criticisms over agency's H1N1 response

CPL Biologicals completes construction of vaccine facility in Dholka, India

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

2010 International Conference on Emerging Infectious Diseases at Atlanta, Georgia

Regeneron's ARCALYST prevents gout attacks in Phase 3 study of patients initiating allopurinol therapy

Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate

Repligen's fiscal 2010 total revenue decreases to $20,971,000

NWBT announces release of new detailed report by Pharmaceuticals and Biotech Analyst

Experts call on international community to commit attention and resources to cervical cancer prevention

White paper advocates strategies to reduce barriers to HPV vaccination, cervical cancer prevention

Phase 3 clinical study: Ipilimumab boosts, sustains immune system responses against melanoma tumors

Immunosignature technique provides pre-symptomatic diagnosis for broad range of ailments

Lytix Biopharma, KAEL-GemVax granted approval for GV1001/LTX-315 combination cancer therapy study

Gates Foundation announces 5-year, $1.5 billion commitment for maternal, child health

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in